How should restless legs syndrome be evaluated and managed in a patient taking hydroxychloroquine (Plaquenil) 200‑400 mg daily?

Management of Restless Legs Syndrome in Patients Taking Hydroxychloroquine

Hydroxychloroquine (Plaquenil) does not directly cause or worsen restless legs syndrome, so if RLS develops in a patient taking this medication, evaluate and treat the RLS according to standard guidelines without discontinuing the hydroxychloroquine. 1

Initial Assessment

Check morning fasting iron studies (ferritin and transferrin saturation) after withholding iron supplements for at least 24 hours, as iron deficiency is a key modifiable factor in RLS pathophysiology. 1

• Initiate iron supplementation if ferritin ≤75 ng/mL or transferrin saturation <20%—these thresholds are higher than general population guidelines because brain iron deficiency plays a central role in RLS even when serum iron appears normal. 1
• Use oral ferrous sulfate 325–650 mg daily (or every other day to improve tolerability) or IV ferric carboxymaltose 750–1000 mg for rapid correction if oral iron fails or is not tolerated. 1

Review all current medications for RLS-exacerbating agents, including serotonergic antidepressants, dopamine antagonists (antipsychotics, metoclopramide), and centrally acting antihistamines (diphenhydramine). 1, 2

• Hydroxychloroquine is not listed among medications that trigger or worsen RLS in current guidelines. 1, 3
• The FDA label for Plaquenil does not mention RLS as an adverse effect. 3

Assess for untreated obstructive sleep apnea, as this can worsen RLS symptoms and influences medication safety (particularly with gabapentinoids and opioids). 1

First-Line Pharmacologic Therapy

Alpha-2-delta ligands (gabapentin, gabapentin enacarbil, or pregabalin) are strongly recommended as first-line treatment with moderate certainty of evidence, superseding older recommendations that favored dopamine agonists. 1, 4

Gabapentin Dosing

• Start 300 mg three times daily (900 mg/day total). 1
• Titrate by 300 mg/day every 3–7 days until reaching maintenance dose of 1800–2400 mg/day divided TID. 1
• Maximum studied dose is 3600 mg/day, well-tolerated in clinical trials. 1
• Common side effects include somnolence and dizziness, typically transient and mild. 1

Pregabalin Alternative

• Allows twice-daily dosing with potentially superior bioavailability compared to regular gabapentin. 1
• Start 50 mg TID or 75 mg BID; after 3–7 days increase to 300 mg/day, then by 150 mg every 3–7 days as tolerated. 1
• Maximum dose 600 mg/day. 1

Medications to Avoid

Dopamine agonists (pramipexole, ropinirole, rotigotine) are NOT recommended for standard use due to a 7–10% annual risk of augmentation—a paradoxical worsening of symptoms with earlier onset, increased intensity, and spread to arms/trunk. 1, 4

• These agents may be considered only for short-term use in patients who prioritize immediate symptom relief over long-term safety, but this is explicitly not the standard approach. 1, 5

Strongly recommended against: cabergoline, bupropion, carbamazepine, clonazepam, valproic acid. 1

Refractory Cases

If symptoms persist despite optimized iron status (ferritin >75 ng/mL, transferrin saturation >20%) and adequate trial of alpha-2-delta ligands at therapeutic doses:

Extended-release oxycodone (5–10 mg at bedtime) or other low-dose opioids (methadone 5–10 mg daily, buprenorphine) are conditionally recommended with moderate certainty of evidence. 1, 4

• Long-term studies show only modest dose escalation over 2–10 years and relatively low abuse risk in appropriately screened patients. 1, 6
• Screen for opioid-use-disorder risk and evaluate for untreated sleep apnea before initiating, as opioids increase respiratory depression risk. 1
• Monitor for constipation (most common adverse effect) and prescribe prophylactic stool softeners. 1

Bilateral high-frequency peroneal nerve stimulation is a non-pharmacologic alternative with conditional recommendation and moderate certainty. 1

Monitoring and Follow-Up

• Reassess iron studies every 6–12 months even after symptom resolution, as brain iron deficiency may persist despite normal serum parameters. 1, 7
• Monitor for side effects of alpha-2-delta ligands, particularly dizziness and somnolence. 1
• Evaluate both nighttime symptom relief and daytime functioning (alertness, concentration, mood). 1

Critical Pitfalls to Avoid

• Do not discontinue hydroxychloroquine based on RLS symptoms, as it is not an established RLS trigger. 1, 3
• Do not use dopamine agonists as first-line therapy given current evidence favoring alpha-2-delta ligands and high augmentation risk. 1, 4
• Do not assume "normal" ferritin is adequate—the RLS-specific threshold is ≤75 ng/mL, not the general population cut-off. 1
• Do not use clonazepam as monotherapy—it provides only sedation without addressing underlying RLS pathology. 1, 7